Gpr68-IN-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: Gpr68-IN-1
• 英文别名: 5-ethyl-5'-naphthalen-1-ylspiro[1H-indole-3,2'-3H-1,3,4-thiadiazole]-2-one
• 化学式: C₂₁H₁₇N₃OS
• 分子量: 359.4
• InChiKey: FXTVKHHEAAQZHM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  26
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  78.8
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] SMALL MOLECULE INHIBITORS OF GPCR GPR68 AND RELATED RECEPTORS<br/>[FR] INHIBITEURS À PETITES MOLÉCULES DE RCPG GPR68 ET RÉCEPTEURS ASSOCIÉS POUR LE TRAITEMENT DU CANCER, DU GLIOBLASTOME ET D'AUTRES INDICATIONS
  申请人：UNIV MARYLAND

  公开号：WO2020214896A1

  公开（公告）日：2020-10-22

  The invention relates to a class of small molecule inhibitors of GPR68/OGR1, a proton-sensing/stretch-sensing/sheer-stress-sending G-protein coupled receptor, and related receptors GPR4 and GPR65. These inhibitors are useful as a therapeutic for glioblastoma and other neoplasms, as a monotherapy or adjuvant, and also can be used as a treatment for other conditions, such as osteoporosis, inflammatory bowel disease, autoimmune and chronic inflammatory diseases such as multiple sclerosis and inflammatory pain syndromes, GERD, aspiration pneumonitis, bacterial and viral pneumonia, COPD, acute respiratory distress syndrome (ARDS), and COVID-19.

  该发明涉及一类GPR68/OGR1的小分子抑制剂，这是一种质子感应/拉伸感应/剪切应力发送的G蛋白偶联受体，以及相关的受体GPR4和GPR65。这些抑制剂可用作治疗胶质母细胞瘤和其他肿瘤的药物，作为单独治疗或辅助治疗，也可用作治疗其他疾病，如骨质疏松症、炎症性肠病、自身免疫和慢性炎症性疾病（如多发性硬化和炎症性疼痛综合征）、胃食管反流病、吸入性肺炎、细菌和病毒性肺炎、慢性阻塞性肺疾病、急性呼吸窘迫综合征（ARDS）和COVID-19的治疗。
• SMALL MOLECULE INHIBITORS OF GPCR GPR68 AND RELATED RECEPTORS
  申请人：University of Maryland, Baltimore

  公开号：EP3955922A1

  公开（公告）日：2022-02-23
• SPECIFIC INHIBITORS OF PROTEIN P21 AS THERAPEUTIC AGENTS
  申请人：BADEN-WÜRTTEMBERG STIFTUNG GMBH

  公开号：US20150210717A1

  公开（公告）日：2015-07-30

  The present invention relates to novel inhibitors of p21. These inhibitors are useful as therapeutic agents for promot ing cell regeneration and in the treatment of cancer. Improvement of cell regeneration is particularly desirable in patients of old age or in patients suffering from chronic diseases, acute or chronic injuries.
• SMALL MOLECULE INHIBITORS OF GPCR GPR68 AND RELATED RECEPTORS FOR TREATING CANCER, GLIOBLASTOMA, AND OTHER INDICATIONS
  申请人：UNIVERSITY OF MARYLAND, BALTIMORE

  公开号：US20220202785A1

  公开（公告）日：2022-06-30

  The invention relates to a class of small molecule inhibitors of GPR68/OGR1, a proton-sensing/stretch-sensing/sheer-stress-sending G-protein coupled receptor, and related receptors GPR4 and GPR65. These inhibitors are useful as a therapeutic for glioblastoma and other neoplasms, as a monotherapy or adjuvant, and also can be used as a treatment for other conditions, such as osteoporosis, inflammatory bowel disease, autoimmune and chronic inflammatory diseases such as multiple sclerosis and inflammatory pain syndromes, GERD, aspiration pneumonitis, bacterial and viral pneumonia, COPD, acute respiratory distress syndrome (ARDS), and COVID-19.
• [EN] SPECIFIC INHIBITORS OF PROTEIN P21 AS THERAPEUTIC AGENTS<br/>[FR] INHIBITEURS SPÉCIFIQUES DE LA PROTÉINE P21 COMME AGENTS THÉRAPEUTIQUES
  申请人：BADEN WUERTTEMBERG STIFTUNG GMBH

  公开号：WO2014041125A1

  公开（公告）日：2014-03-20

  The present invention relates to novel inhibitors of p21. These inhibitors are useful as therapeutic agents for promoting cell regeneration and in the treatment of cancer. Improvement of cell regeneration is particularly desirable in patients of old age or in patients suffering from chronic diseases, acute or chronic injuries.